Featured Content |Content Library
A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial ...
Dana-Farber Cancer Institute is proud to announce that 33 of its researchers have been named to the Highly Cited Researchers list of 2022 released today by the Institute for Scientific Information at Clarivate.
A novel antibody drug conjugate therapy whose clinical trial testing has been co-led by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November ...
Fifty years ago, Brigham and Women's Hospital and Boston Children's Hospital initiated a joint bone marrow transplant program. In the early 1980s, Dana-Farber launched its own transplant program.
Receive Dana-Farber's e-newsletter, Momentum, to learn of advances in cancer research and care, current clinical trials, and upcoming CME programs.
- American Society of Hematology (ASH) Annual Meeting
- San Antonio Breast Cancer Symposium
- Center for Protein Degradation - Royal Chemistry Society
- Breast Cancer Treatment
- Research News Updates
- Faculty Updates
- Symposium Highlights 75 Years of Dana-Farber Science